Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

56.93
+0.72001.28%
Post-market: 56.930.00000.00%19:30 EDT
Volume:2.88M
Turnover:163.61M
Market Cap:32.85B
PE:30.54
High:57.08
Open:56.03
Low:55.72
Close:56.21
52wk High:64.38
52wk Low:35.23
Shares:576.94M
Float Shares:392.53M
Volume Ratio:0.95
T/O Rate:0.73%
Dividend:0.91
Dividend Rate:1.60%
EPS(TTM):1.86
EPS(LYR):1.78
ROE:13.97%
ROA:5.09%
PB:4.81
PE(LYR):31.96

Loading ...

Zealand Pharma Sells Rusfertide Royalty Interests to Royalty Pharma for USD 100 Million

Reuters
·
Aug 13

Royalty Pharma Publishes Transcript of Q2 2026 Financial Results Call

Reuters
·
Aug 11

J.P. Morgan Keeps Their Buy Rating on Royalty Pharma (RPRX)

TIPRANKS
·
Aug 11

Canada's DRI Healthcare Q2 Income Rises, Helped by Milestone Events in Royalty Portfolio

Reuters
·
Aug 08

Xenetic Biosciences Q2 Royalty Revenue Rises on Takeda Sublicense

Reuters
·
Aug 07

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Royalty Pharma price target raised to $70 from $66 at Citi

TIPRANKS
·
Aug 06

Biopharma Firm MannKind Q2 Posts Net Loss on Product Launch Expenses

Reuters
·
Aug 06

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06

Royalty Pharma PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Royalty Pharma Q2 Adj. EPS $1.32 Beats $1.28 Estimate, Sales $674.000M Miss $693.190M Estimate

Benzinga Earnings
·
Aug 05

Royalty Pharma Q2 Net Income Falls, Revenue Rises

MT Newswires Live
·
Aug 05

Royalty Pharma Q2 GAAP Net Income Attributable to Company Falls 44% to $18 Million; Non-GAAP Adjusted Ebitda Rises 16% to $736 Million

Reuters
·
Aug 05

Royalty Pharma Q2 Adjusted Ebitda Beats Estimates

Reuters
·
Aug 05

Royalty Pharma Reports Second Quarter 2026 Results

THOMSON REUTERS
·
Aug 05

Royalty Pharma: Outlook 2026 Portfolio Receipts $3,400 Mln to $3,500 Mln, Interest Paid $350 Mln to $360 Mln

THOMSON REUTERS
·
Aug 05

Royalty Pharma Names Greg Raskin SVP, Head of Academic Initiatives

Reuters
·
Aug 03

Royalty Pharma Appoints Greg Raskin as Senior Vice President, Head of Academic Initiatives

THOMSON REUTERS
·
Aug 03